<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04803084</url>
  </required_header>
  <id_info>
    <org_study_id>VICC BRE 20104</org_study_id>
    <secondary_id>P50CA098131</secondary_id>
    <nct_id>NCT04803084</nct_id>
  </id_info>
  <brief_title>Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment</brief_title>
  <official_title>Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laura Kennedy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking at how an imaging test could help doctors understand if a patient with&#xD;
      early breast cancer will respond to drugs that use the patient's immune system to fight&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      - To evaluate serial multiparametric MRI as an early marker for tumor immune response to an&#xD;
      immune checkpoint inhibitor agent&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
        -  To assess the potential of early treatment imaging changes on MRI to discern final tumor&#xD;
           treatment response&#xD;
&#xD;
        -  To assess the prognostic potential of MRI features&#xD;
&#xD;
      Correlative:&#xD;
&#xD;
        -  To correlate MRI features with immunophenotypes (i.e. hot and cold tumors)&#xD;
&#xD;
        -  To evaluate the association of MRI features with other known biomarkers of immune&#xD;
           checkpoint inhibitor response&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlate dynamic-contrast enhanced MRI characteristics</measure>
    <time_frame>Baseline up to about 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlate diffusion weight imaging MRI characteristics</measure>
    <time_frame>Baseline up to about 14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate association between MRI features and pathologic response</measure>
    <time_frame>Baseline up to about 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate association between MRI features and recurrence-free survival</measure>
    <time_frame>Baseline up to about 14 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Triple-negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Advanced Pathology</arm_group_label>
    <description>Breast magnetic resonance imaging (MRI) as a preliminary predictive biomarker for breast cancer treatment response.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tempus assay</intervention_name>
    <description>Blood collection</description>
    <arm_group_label>Advanced Pathology</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Advanced pathology 1</intervention_name>
    <description>Tissue procurement (from diagnostic biopsy)</description>
    <arm_group_label>Advanced Pathology</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Advanced pathology 2</intervention_name>
    <description>Tissue procurement (from research biopsy)</description>
    <arm_group_label>Advanced Pathology</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women and men at least 18 years of age that have a new diagnosis of invasive breast cancer&#xD;
        with clinical stage I - III disease or regional stage IV with metastasis to the&#xD;
        supraclavicular nodes only.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Women and men at least 18 years of age.&#xD;
&#xD;
          -  Have a new diagnosis of invasive breast cancer with clinical stage I - III disease or&#xD;
             regional stage IV with metastasis to the supraclavicular nodes only&#xD;
&#xD;
          -  Hormone receptor negative (estrogen-receptor &lt; 5% and/or progesterone-receptor &lt; 5%)&#xD;
&#xD;
          -  Human epidermal growth factor receptor 2 (HER2) negative by immunohistochemistry or&#xD;
             fluorescence in situ hybridization (FISH)&#xD;
&#xD;
          -  Enrollment in a neoadjuvant clinical trial that includes the evaluation of&#xD;
             immunotherapy as a part of the regimen; patient must be randomized to a treatment arm&#xD;
             (including the control arm) prior to enrolling in this study&#xD;
&#xD;
          -  Planning to undergo surgical resection and subsequent adjuvant therapy as per the&#xD;
             treatment clinical trial or the clinical provider&#xD;
&#xD;
          -  Have tissue available for additional correlative studies OR planned to undergo an&#xD;
             additional pre-treatment biopsy for additional tissue acquisition as per provider or&#xD;
             the treatment clinical trial&#xD;
&#xD;
          -  Be a candidate for MRI imaging.&#xD;
&#xD;
          -  Be willing to comply with scheduled visits required for the trial.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Systemic or locoregional treatment for the current episode of breast cancer prior to&#xD;
        baseline breast MRI.&#xD;
&#xD;
          -  Poor visualization of the tumor on the initial breast MRI (investigator discretion)&#xD;
&#xD;
          -  Pregnant or nursing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Kennedy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanderbilt-Ingram Service for Timely Access</last_name>
    <phone>800-811-8480</phone>
    <email>cip@vumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanderbilt-Ingram Service for Timely Access</last_name>
      <phone>800-811-8480</phone>
      <email>cip@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Laura Kennedy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Laura Kennedy</investigator_full_name>
    <investigator_title>Sponsor Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>TEMPO</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

